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Abstract
Uracil is a natural base of RNA but may appear in DNA through two different pathways including
cytosine deamination or misincorporation of deoxyuridine 5'-triphosphate nucleotide (dUTP)
during DNA replication and constitutes one of the most frequent DNA lesions. In cellular
organisms, such lesions are faithfully cleared out through several universal DNA repair
mechanisms, thus preventing genome injury. However, several recent studies have brought some
pieces of evidence that introduction of uracil bases in viral genomic DNA intermediates during
genome replication might be a way of innate immune defence against some viruses. As part of
countermeasures, numerous viruses have developed powerful strategies to prevent emergence of
uracilated viral genomes and/or to eliminate uracils already incorporated into DNA. This review
will present the current knowledge about the cellular and viral countermeasures against uracils in
DNA and the implications of these uracils as weapons against viruses.
Background
Uracils in DNA may arise either from incorporation of
dUTP in place of thymidine 5'-triphosphate (dTTP) or
from the generation of uracils in DNA consecutive to
spontaneous or enzymatic deaminations of cytosines
which, if unrepaired, will lead to non-mutagenic U:A or
mutagenic U:G mispairs, respectively. Although U:A mis-
pairs resulting from excess of cellular dUTP pool levels are
not mutagenic per se, they elicit a cycle of dUMP incorpo-
ration into DNA followed by the removal of uracil base by
cellular uracil DNA glycosylases (UNG) and reincorpora-
tion of dUMP during the synthesis phase. The end point
of this process is the appearance of strand breaks and the
loss of DNA integrity. In nonproliferating cells such as
macrophages, quiescent lymphocytes or neurons the
intracellular deoxynucleotide pool is low and imbal-
anced, with high levels of dUTP, due to the limited expres-
sion of the deoxyuridine 5'-triphosphatase nucleotide
hydrolase (dUTPase) that otherwise controls the dUTP/
dTTP ratio. Consequently, viruses that replicate in this
adverse cellular context have a high probability to incor-
porate dUTP in their genome during viral replication.
They have thus acquired strategies consisting in concen-
trating dUTPase or UNG activities in close proximity to
their replication machinery. Most often they have done so
by encoding themselves viral dUTPase and/or UNG in
order to compensate for the low levels of these cellular
enzymes. In the following we will focus on the different
ways by which uracils are introduced into cellular and
viral DNA and on the resulting biological consequences
when uracils remain unrepaired, with a special attention
to HIV-1 lentivirus. HIV-1 replicates in nondividing cells
but does not encode dUTPase nor UNG. However, HIV-1
fights the detrimental uracilation of its genome induced
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by members of the APOBEC family, which are cytosine
deaminases able to convert cytosine to uracil residues,
through the Vif protein. Vif impedes the packaging of
APOBEC members avoiding excessive G-to-A hypermuta-
tions within viral genome. The role in virus life cycle of the
host-derived UNG (UNG2) enzyme that is packaged into
HIV-1 virions will be discussed.
Uracils in cellular or viral DNA may derive from different 
sources
The common RNA base uracil (U) that is substituted by
thymine (T) in DNA is able to naturally pair with adenine
(A) but can also mispair with guanine (G). The U:A pair
in DNA results from the incorporation of dUTP by
polymerases and constitutes a non-mutagenic event per se
that can nonetheless alters promoters functions [1]. How-
ever, U:A pair may be a cytotoxic lesion or even become a
mutagenic event when chromosomal abasic sites (AP-
sites) are generated after the removal of uracils by cellular
repair mechanisms [2]. The U:G mispair is a non-blocking
DNA replication lesion and occurs after the deamination
of a cytosine to uracil. This lesion is mutagenic, leading to
a G-to-A transition mutation in one of the two daughter
strands after DNA replication.
The incorporation of dUTP into DNA during replication
has been estimated to be up to 104 uracil residues in
human genome per day [3] and represents the major
source of uracils in DNA [4]. In eukaryotic cells, dUTP is
synthesized from the phosphorylation of dUDP arising
either from UDP under the action of the ribonucleoside
diphosphate (rNDP) reductase or from the phosphoryla-
tion of dUMP, which is an essential intermediate for the
synthesis of the intracellular dTTP pool and therefore con-
stitutes a permanent source of dUTP (Fig. 1). DNA
polymerases from eukaryotes, prokaryotes and viruses are
not able to discriminate dUTP from dTTP. Thus the incor-
poration of dUTP directly depends on its intracellular
concentration. Under physiological conditions, the con-
centration of dUTP and dTTP in the cell have been esti-
mated to be ~0.2 μM and 37 ± 30 μM, respectively [5]
meaning that the normal intracellular dUTP/dTTP ratio is
below or close to 1%. However, some cell types such as
HT29 cell line, primary spleen cells, macrophages or qui-
escent lymphocytes display significantly higher dUTP lev-
els that can even exceed those of dTTP [6-8].
The deamination of cytosine residues to uracil residues in
DNA can arise either from a spontaneous (non-enzy-
matic) or an enzymatic process. Spontaneous deamina-
tion is a frequent event that has been estimated by
chemical measurements and genetic assays to occur
between 70 to 200 times per cell per day [9]. In addition
to cytosine deaminases, the mammalian genome encodes
two distinct enzymes able to convert cytosine to uracil,
namely the (cytosine-5)-methyltransferase and the
APOBEC cytidine deaminase. The (cytosine-5)-methyl-
transferase, is in charge of the conversion of cytosines
within CpG islets to 5-methylcytosines. In mammalian
cells, 5-methylcytosines represent about 2 to 7% of
cytosines and constitute a regulatory system for transcrip-
tion and can confer epigenetic informations [10]. The
conversion starts with the formation of a covalent bond
between the enzyme and the cytosine, leading to a tran-
sient dihydropyrimidine intermediate product that is
quickly subjected to spontaneous deamination. The
enzyme next catalyzes the transfer of a methyl group to
the cytosine. This latter reaction uses the S-adenosylme-
thionine (SAM) molecule as a methyl donor. Thus, a cyto-
sine deamination to uracil may occur in the case of the
abortive catalysis by (cytosine-5)-methyltransferase [11]
or in the presence of a low cellular concentration of SAM
[12].
The APOBEC cytidine deaminase family members are
able to deaminate cytosines within DNA and/or RNA
molecules. The first member of this family, APOBEC1
(apolipoprotein B mRNA editing catalytic subunit 1), has
been identified as the enzyme responsible for the tissue-
specific deamination of the C6666 of the apolipoprotein B
mRNA, leading to a premature stop codon and the expres-
sion of a truncated form of the apolipoprotein B lipid-
transport protein in gastrointestinal tissues [13,14]. The
APOBEC1 protein acts exclusively as a RNA-editing
enzyme in the small intestine (where it is exclusively
expressed) but can, however, deaminate cytosines present
in chromosomal DNA of living bacteria [15,16]. These
results drew attention to the possibility that APOBEC pro-
teins could deaminate either RNA or DNA under different
cellular conditions [15,16]. Other members of the
APOBEC cytidine deaminase family, including AID (acti-
vation-induced cytidine deaminase), APOBEC2, the
APOBEC3 sub-family and APOBEC4, have next been dis-
covered and the biological function of several of them has
been studied. At this time, no function has yet been attrib-
uted to APOBEC2 and APOBEC4 proteins. The AID pro-
tein, whose expression is restricted to activated mature B
cells, has been identified as a key factor of antibody diver-
sification [17]. AID is required to deaminate specifically
some cytosines in ssDNA of variable and switch regions of
the Ig gene locus, allowing somatic hypermutation (SHM)
and the class-switch recombination (CSR) processes that
are needed to generate antibody diversity in response to
antigens [18-21]. The APOBEC3 sub-family has been dis-
covered when human APOBEC3G (hA3G) was reported
as a host cell restriction factor for HIV replication [22].
Subsequently, it has been reported that seven APOBEC3
proteins, so-called APOBEC3A, 3B, 3C, 3DE (the 3D and
3E genes encode the N- and C-terminal domains of the
3DE protein, respectively), 3F, 3G and 3H, are encoded byRetrovirology 2008, 5:45 http://www.retrovirology.com/content/5/1/45
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the human genome [23,24]. These APOBEC3 proteins,
with the exception of APOBEC3H, have been shown to
exhibit antiviral effects against a variety of viruses, includ-
ing numerous retroviruses such as HIV, SIV, MLV, HTLV
and foamy viruses, hepatitis B virus and adeno-associated
virus (AAV) (reviewed in [25]) (Fig. 2). The absence of
antiviral effect of human APOBEC3H, in contrast to its
Old World monkey (OWM) counterpart, may be
explained by a poor expression [26]. The antiviral effect
displayed by other human APOBEC3 proteins, with the
exception of APOBEC3A, was associated with numerous
cytosine deaminations (known as "editing") within the
viral cDNA leading to lethal G-to-A mutations (reviewed
in [25]). Indeed, APOBEC3A has been found to exert anti-
viral effects without cytosine deaminations although
recent reports showed that it was capable of editing in vitro
on single-stranded DNA [27] and on the cDNA of the
avian alpharetrovirus RSV thereby inhibiting its infectivity
[28]. Studies of deaminase-defective APOBEC3 mutants
have shown that APOBEC3G and APOBEC3F contain
antiviral determinants that can act independently of the
editing process [29,30]. However, a recent study reported
Biosynthesis pathways of ribonucleotides and deoxyribonucleotides in mammalian cells and the possible consequence of the  misincorporation and repair of uracil residues in DNA Figure 1
Biosynthesis pathways of ribonucleotides and deoxyribonucleotides in mammalian cells and the possible consequence of the 
misincorporation and repair of uracil residues in DNA. De novo synthesis of AMP, CMP, GMP and UMP ribonucleotides allows 
the formation of dATP, dCTP, dGTP, dTTP and dUTP deoxyribonucleotides, which can be readily incorporated in DNA by 
cellular DNA polymerases. Note that dTTP derives from dUTP hydrolysis. Abbreviations: A, adenine; C, cytosine; G, guanine; 
T, thymine; U, uracil; MP, monophosphate; DP, diphosphate; TP, triphosphate; rNDP, ribonucleotide diphosphate; NMPK, 
nucleotide monophosphate kinase; NDPK, nucleotide diphosphate kinase.
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that this previously described antiviral effect of the deam-
inase-defective APOBEC3G mutants was negligible as
compared to the wild-type protein when equal amounts
of these proteins were packaged into viral particles [31].
Beside the antiviral function of APOBEC3 proteins against
exogenous viruses, some inhibitory effects have been
reported on intracellular targets like the IAP, MusD or Ty1
Long Terminal Repeat (LTR)-retrotransposons and LINE-
1 or Alu  non-LTR retrotransposons through a general
deaminase-dependent mechanism (again the with excep-
tion of APOBEC3A) [25]. Accordingly, several studies sup-
port the notion that one of the cellular functions of
APOBEC3 proteins could be to prevent the propagation of
mobile elements in their host genomes. In a general way,
uracils coming from the action of the AID or the
APOBEC3 proteins appear to be central actors in the adap-
tive or innate immune response, respectively.
Genomic uracils are highly controlled in cells
Eukaryotic and prokaryotic cells have evolved in setting
up two mechanisms to impede the presence of uracils in
DNA, bringing to light the highly deleterious effects of
genomic uracils if unrepaired. The first mechanism in
place prevents the incorporation of dUTP by acting
directly on the intracellular pool of dUTP through the
action of dUTPase, while the second is responsible for the
APOBEC3 family members and their associated roles in exogenous viruses and endogenous retroelements restriction Figure 2
APOBEC3 family members and their associated roles in exogenous viruses and endogenous retroelements restriction. Data 
are compiled from [27, 77, 87, 90, 126-140].
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excision of uracil once present in DNA through an univer-
sal DNA repair process called base excision repair (BER)
and the use of enzymes known as uracil-DNA glycosylases
(UNGs).
The dUTPase is a ubiquitous enzyme that is well con-
served in all organisms. This protein maintains a low level
of intracellular dUTP by converting dUTP to dUMP and
inorganic pyrophosphate and also allows the biosynthesis
of nucleotides derived from thymidine [32] (Fig. 1). The
human dUTPase gene encodes, through alternative splic-
ing, two isoforms that localize to either the mitochon-
drion or nucleus [33]. The expression of the nuclear form
is cell-cycle regulated with a high expression in the S phase
of dividing cells that contrasts to a nearly undetectable
expression in differentiated and non-dividing cells [34].
Although no human dUTPase deficiency has been
observed, the absence of the dUTPase activity in prokary-
otes and S. cerevisiae has demonstrated its necessity for cell
viability. In addition, partial deficiency leads to enhanced
frequency of spontaneous mutations, recombinations
and DNA fragmentation [35-39].
The BER process is one of the cellular DNA repair mecha-
nisms responsible for correcting most of common forms
of DNA damage including the removing of genomic
uracils. The DNA repair process has been extensively sub-
jected to reviews [40] and will be shortly introduced here.
It involves the recognition and the excision of an inappro-
priate base by a specific DNA glycosylase leading to an
abasic site (AP-site) that is further cleaved on its 5' side by
an apurinic/apyrimidinic (AP)-endonuclease APE, leaving
a free 3'-OH end and a 5'-deoxyribose phosphate (dRP)
group. The dRP group is then incised on its 3' side via the
lyase activity (dRPase) of the DNA polymerase β (pol β)
for the short patch repair pathway while a short oligonu-
cleotide is cleaved by the flap endonuclease 1 (FEN1) for
the long patch repair pathway. Finally, the resulting gap is
then filled in by pol β and/or pol δ/ε and sealed by the
DNA ligase I or III. The DNA glycosylases responsible for
the excision of uracils are highly conserved enzymes
expressed in mammals, bacteria, yeast, or herpes- and
poxviruses. In humans, several enzymes with UNG activ-
ity have been described, namely TDG, MBD4, SMUG1,
UNG1 and UNG2 [41]. The UNG2 and SMUG1 enzymes
have been reported as the major enzymes proficient for
removing deaminated cytosines although SMUG1 is
thought to act as a backup of UNG2 [42-44]. UNG2 has
been also reported as the unique enzyme able to perform
the excision of uracil from dUTP misincorporation
[42,43]. The UNG1 and UNG2 enzymes are mitochon-
drial and nuclear isoforms, respectively, generated by
alternative splicing of the human ung gene [45]. Like the
dUTPase, the expression of the nuclear UNG2 form
depends on the cell cycle with high levels in the S phase of
dividing cells, and barely detectable levels in differenti-
ated and non-dividing cells [34]. In contrast to UNG2 that
accumulates in replication foci [42,43], SMUG1 is only
expressed in nucleoli where it may have a specialized role
[44]. UNG-deficiency in mice and in humans leads to
increased accumulation of genomic uracils, confirming its
primary role in the removal of uracil from DNA [46-48].
Although UNG2 is considered to display an antimuta-
genic function, it seems to have an essential role in the
antibody diversification process. The vast repertoire of
antibody molecules, which is essential to detect and fight
pathogens, is generated thanks to profound genomic
changes at the Ig locus in B cells. This process occurs
through numerous somatic hypermutations (SHM) that
lead to the affinity maturation of antibodies, and through
class-switch recombination (CSR) allowing these high
affinity antibodies to gain some effector functions and to
be disseminated across the body. These mechanisms are
initiated from the targeted deamination of cytosines trig-
gered by AID within the Ig locus [18-21]. The AID-gener-
ated uracils lesions are then recognized and excised by
UNG2 enzyme. Replication across the resulting AP-sites
by REV1 and other translesion polymerases results in the
generation of transition mutations at C:G pairs [49,50].
Moreover, some mutations at A:T pairs can also be
observed during the SHM process but the molecular
mechanisms involved remain to be fully understood. The
MSH2-MSH6 mismatch repair proteins could however
recognize U:G mispairs and could be required to generate
A:T mutations [51-54]. A recent study has indicated that
the MSH2-MSH6 heterodimer could prevent the error-free
BER commonly initiated by UNG2 and that UNG2 could
recruit pol η, which appears to be the sole contributor of
A:T mutations [55]. Thus, UNG2 plays a key role in SHM
as well as CSR processes. Indeed, UNG2-deficient humans
cannot ensure CSR and therefore have elevated IgM
amounts and dramatically lowered IgG, IgA and IgE levels
[46]. However, the role of the uracil excision activity of
UNG2 in this process seems not clear and warrants further
studies. Altogether, these data highlight the crucial role of
UNG2 in the adaptative immunity against numerous
pathogens, like bacteria or viruses.
Numerous viruses have evolved strategies to counteract 
uracils
Viruses belonging to the Herpesviridae, Poxviridae and Ret-
roviridae  families have evolved in encoding their own
dUTPase and/or UNG proteins, supporting the idea that
these viruses are sensitive to the presence of uracil residues
in their genome.
The Herpesviridae family contains members that replicate
their dsDNA genome in the nucleus of a variety of cell
types, including some non-dividing cells, such as neurons.Retrovirology 2008, 5:45 http://www.retrovirology.com/content/5/1/45
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The viral dUTPase and UNG of alpha herpesviruses, like
herpes simplex virus (HSV) or varicella zoster virus (VZV),
are not essential in proliferating cells [56-58] but become
critical in non-dividing cells or in an in vivo murine system
[59,60]. Beta herpesviruses, like cytomegalovirus (CMV),
do not encode a functional dUTPase [61] but express their
own UNG that appears to be required in non-dividing
cells to compensate for the very low level of cellular
UNG2 [62,63]. The gamma herpesviruses, like Epstein-
Barr viruses (EBV), Kaposi's sarcoma-associated herpesvi-
ruses (HHV-8) or murine γ-herpesvirus-68 (MHV-68),
also encode a functional UNG and dUTPase [64,65]. The
EBV-encoded UNG was shown to ensure the fidelity of
viral DNA replication and to promote efficient production
of viral DNA [64] and the EBV-encoded dUTPase
expressed by MHV-68 was found to play an important
role in acute infection in the lung [66].
The members of the Poxviridae family, such as vaccinia
virus, replicate their dsDNA exclusively in the cytoplasm
of infected cells. Thereby, due to the total absence of
cytosolic UNG activity, the inactivation of the virally-
encoded UNG leads to an impaired viral replication even
in proliferating cells [67,68]. These data highlight that
uracils in the genome of DNA viruses can impair their rep-
lication and depict the necessity for these viruses to
encode their own dUTPase and/or UNG enzymes to com-
pensate for the lack of cellular counterpart during their life
cycle either in non-dividing cells or in the cytoplasmic
compartment.
Several members of the Retroviridae family, such as β-ret-
roviruses including Mazon-Pfizer monkey virus (MPMV)
or murine mammary tumor virus (MMTV), nonprimate
lentiviruses including the ungulate lentiviruses maedi-
visna virus (MVV) of sheep, the caprine arthritis-encepha-
litis virus (CAEV), the equine infectious anemia virus
(EIAV), the feline immunodeficiency virus (FIV) and the
rabbit endogenous lentivirus type K (RELIK), and even
many endogenous retroviruses including HERV-L, MERV-
L and HERV-K, also encode their own dUTPase protein.
Interestingly, the dUTPase domain of these retroviruses
can be differently located in their genome, either
upstream of protease, or in-between reverse transcriptase
and integrase, or downstream of integrase, indicating that
retroviruses have captured a dUTPase gene during inde-
pendent occasions. This suggests that the need of the
dUTP hydrolysis activity is crucial to confer a selective
advantage for retroviral replication. The virally-encoded
dUTPase protein is expressed as a part of the Gag-pol poly-
protein precursor and is expected to be encapsidated into
viral particles in order to be in close spatial proximity of
the reverse transcriptase [69]. Although the role of β-retro-
viral or endogenous retroviral dUTPases still remains to
be fully determined, the study of the dUTPase of nonpri-
mate lentiviruses revealed that it is required for efficient
replication only in non-dividing cells, [70-74]. It is note-
worthy that other retroviruses members, such as murine
leukemia virus (MLV) related viruses or avian leukemia
virus (ALV) related viruses, do not encode dUTPase. One
can notice that they replicate their genome only in actively
dividing cells, which may explain why they do not need to
encode dUTPase.
Collectively, these data show that (i) although not muta-
genic per se, uracils in viral genomes coming from dUTP
misincorporation alter viral replication, (ii) high dUTP
levels are present in the nucleus of non-dividing cells or in
the cytoplasm of proliferating cells that express low levels
of dUTPase and UNG enzymes, and finally (iii) uracils in
viral DNA genome have to be highly controlled to allow
an efficient viral replication.
APOBEC3 proteins as a part of the innate anti-HIV-1 
immunity and viral countermeasures
Since Sheehy et al. discovered that the human endogenous
APOBEC3G protein acts as a restriction factor to inhibit
HIV-1 replication [22], the question of innate immunity
against viruses has gained much attention. From that
time, several other APOBEC3 proteins, namely
APOBEC3F [75,76], -3B [77,78] and -3DE [79] have been
shown to exert antiviral effects against HIV-1. This restric-
tion effect requires the packaging of APOBEC3 proteins
into virions budding from HIV-1 infected cells. Studies on
the incorporation of these antiviral factors into viral parti-
cles brought conflicting evidences leading to propose that
either a specific interaction with the nucleocapsid (NC)
domain of Gag polyprotein [80-82], or an association
with viral or cellular RNA [83-86] were required for the
encapsidation. Recently, studies with highly divergent
Gag polyproteins [87] or RNase A treatment [83,84,88]
brought more evidence to the second model where
APOBEC3 packaging involves an RNA intermediate. Fol-
lowing the entry of APOBEC3G-containing viral particles
in target cells, virion-associated APOBEC3 proteins trigger
extensive cytosine deaminations to uracils in neosynthe-
sized viral minus-strand DNA [89-92]. This process occurs
through a target site specificity depending on the nature of
the APOBEC3 protein. Thus, APOBEC3G prefers to deam-
inate the dinucleotide CC (underline marks the target) on
minus-strand cDNA [89-92], while APOBEC3F or -3B
favors a TC context [77] and APOBEC3DE selects a GC
context [79]. This event takes place next to the degrada-
tion of the RNA template by the RNase H activity of RT
because (i) the APOBEC3G proteins act only on single-
stranded DNA [93] and (ii) the APOBEC3G activity is
inhibited by viral genomic RNA [94]. The deamination of
cytosine by APOBEC3 proteins leads to lethal G-to-A
hypermutations in viral plus-strand cDNA [89-92,95].
However, in several in vitro experimental assays, someRetrovirology 2008, 5:45 http://www.retrovirology.com/content/5/1/45
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APOBEC3 family members are depicted as able to restrict
some retroviruses, retroelements or other viruses through
mechanisms independent of DNA deaminations
(reviewed in [25]) (Fig. 2). In the case of APOBEC3G, it
has been reported that it exhibits both deaminase-
dependent and deaminase-independent antiviral activi-
ties. The deaminase-independent activity could be due to
directly inhibiting the strand transfer or the processivity of
reverse transcriptase [96,97].
To counteract the editing process and to protect its
genome from G-to-A hypermutations, HIV-1 evolved in
encoding the Vif protein that exhibits the property to bind
APOBEC3G and to induce its proteasomal degradation,
thus depleting APOBEC3G at the site of virion budding
[98-100]. The degradation of APOBEC3G requires the for-
mation of a Vif-Cul5-elongins B and C-Rbx1 complex,
which allows the polyubiquitination of APOBEC3G. It
has also been reported that Vif could interfere with
APOBEC3G translation [101] or directly with its packag-
ing [102]. Interestingly, the Vif-mediated degradation
appears to be more potent on APOBEC3G than on
APOBEC3F or -3DE and has not been observed for
APOBEC3B [98-100]. In addition, the aspartate residue at
position 128 of APOBEC3G from different species has
been reported to drive the interaction with Vif and thus to
govern species specificity [102-106]. Indeed, HIV-1 Vif
protein was efficient to bind to and inhibit the packaging
of human APOBEC3G but not that of the simian (African
green monkey or rhesus monkey) or murine counterparts
[102,107].
Collectively, these data show that cells take advantage of
uracil susceptibility displayed by numerous viruses to
inhibit their propagation through the expression of the
APOBEC3 family members. Unfortunately, HIV-1 illus-
trates the high capacity of viruses to evolve rapidly and to
develop mechanisms to thwart this innate antiviral
immunity.
Primate HIV-1 lentivirus controls uracils within viral DNA
Lentiviruses are divided into nonprimate and primate
subgroups and share common characteristics, such as the
ability to infect non-dividing cells and to replicate their
genome in the cytoplasm of infected cells. In this cellular
context, nonprimate lentiviruses control the deleterious
uracilation of their genome through the expression of a
virally-encoded dUTPase. The analysis of primate lentivi-
rus genomes reveals that they do not encode dUTPase nor
UNG-like enzymes. Using a yeast two-hybrid screen, cel-
lular UNG2 was shown to associate with the accessory
HIV-1 Vpr protein [108] and to be incorporated into HIV-
1 viral particles [109-114]. Although Vpr was initially sus-
pected to play a role in the packaging of UNG2 [110,111],
it was later demonstrated by three other groups that
UNG2 packaging was independent of the presence of Vpr
in viral particles [109,112,113,115,116]. Indeed, the inte-
grase (IN) domain in the context of the HIV-1 Gag-Pol
precursor was identified as the sole determinant to target
UNG2 into virions and we have demonstrated that the
leucine 172 residue of IN was critical for UNG2 encapsi-
dation [109,115]. The UNG2 packaging was specific to
HIV-1, as neither HIV-2 nor simian immunodeficiency
virus (SIV) packaged UNG2 [116]. It remains to be deter-
mined whether the latter package another cellular UNG or
whether they manage to circumvent the uracilation of
their genomes through other means.
Although it has been shown that Vpr could participate in
the fidelity of reverse transcriptase [110], the role of the
Vpr-UNG2 association remains to be evaluated. Interest-
ingly, recent results showed that the expression of Vpr in
B-cells had a dominant-negative effect on the class switch
recombination (CSR) events [117]. This effect appeared to
be dependent on the interaction of Vpr with the WxxF
motif contained in UNG2 suggesting that Vpr could com-
pete with some endogenous Vpr-like factors important for
UNG function in CSR. Indeed, the CSR is initiated by AID
and the AID-induced uracils are removed by a UNG2- or
a MSH2-dependent mechanism [118], leading to a not
fully characterized dsDNA cleavage step required for CSR
(reviewed in [119]). By analogy, it is possible that the Vpr-
UNG2 complex may play a role in inhibiting dsDNA
cleavages subsequent to the UNG2-induced removal of
uracils in viral cDNA. This assumption may explain why
the infectivity of HIV-1 virions that contain small
amounts of APOBEC-induced uracils was increased by
Vpr [113] and why Vpr seems to be important for viral
replication in non-dividing cells [111]. Future experi-
ments demonstrating a direct implication of the Vpr-UNG
complex in the protection of dsDNA from cleavage are
awaited. Another point that deserves future investigations
concerns the fact that Vpr could potentially target
hAPOBEC3G, which contains in its sequence two WxxF
motifs. If such a Vpr-hAPOBEC3G interaction exists, it
could assign an additional role of Vpr as a back-up of Vif.
The role of the virion-associated UNG2 in the viral life
cycle was evaluated by our laboratory through the specific
depletion of UNG2 by RNA interference-mediated knock-
down and through the inhibition of UNG2 catalytic activ-
ity by the expression of the uracil-DNA glycosylase inhib-
itor (Ugi) in virus producing cells [120]. It was found that
HIV-1 viruses produced from dividing as well as nondi-
viding UNG2-deficient cells were noninfectious, demon-
strating that UNG2 within the viral particle is essential for
infectivity. This also demonstrated that the depletion of
UNG2 in viral particles could not be compensated by
endogenous UNG2 present in target cells, suggesting that
the spatial proximity of UNG2 and the replicationRetrovirology 2008, 5:45 http://www.retrovirology.com/content/5/1/45
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enzymes in the viral nucleocapsid is important. In addi-
tion, the targeting of the CAEV dUTPase into UNG2-defi-
cient viral particles was able to rescue the viral infectivity,
pointing out that dUTP misincorporation could be at the
origin of a lethal reverse transcription process. Indeed,
HIV-1 lysates contained all necessary factors to repair
uracils originating from dUTP misincorporation during
the reverse transcription process [120,121]. These data
pointed out that, to prevent dUTP misincorporations,
HIV-1 is endowed with an original uracil BER pathway
that is initiated by UNG2 and associated with a previously
unknown dNTP-dependent AP-endonuclease activity of
reverse transcriptase (RT) [120]. Although others [110]
and we [121] failed to identify the human AP-endonucle-
ase APE1 within HIV-1 particles, a recent report indicated
that APE1 molecules could be detected in viral particles
[114]. The presence of APE1 within viral particles could
participate in association with UNG2 and RT to the repair
of dUTP misincorporations and could thus have a redun-
dant function in HIV-1 particles. Meanwhile, the main
role of APE1 within viral particles seems rather to be the
degradation of APOBEC3G-edited nascent HIV-1 DNA
after the excision of uracils by UNG2 [114], suggesting a
specialized function of UNG2 and APE1 hijacked by the
cell to amplify the anti-HIV-1 effect of APOBEC3G in the
absence of Vif. It should be mentioned that the degrada-
tion of newly synthesized transcripts cannot be performed
by the dNTP-dependent AP-endonuclease activity of RT
because (i) the RT can cleave UNG2-induced AP-sites only
during the reverse transcription step, i. e. when a template
is available (be it RNA or DNA) [120,122], (ii) the sub-
strate for APOBEC3G is the ssDNA [93,95] and, (iii) the
degradation of the viral RNA template by the RNase H
activity of RT, which inhibits the APOBEC3G activity [94],
is a prerequisite for the cytosine deamination process
[93,95].
Our data demonstrating that UNG2 was necessary for
viral infectivity are in sharp contrast with data from two
other groups [112,114] showing that UNG2 was some-
what dispensable for HIV-1 replication. Kaiser and Emer-
man reported that, although UNG2 was efficiently
encapsidated into HIV-1 virions, it played no role in infec-
tivity, neither for wild type (WT) viruses nor for Vif-minus
viruses in the presence of APOBEC3G [112]. In contrast,
Yang's group has reported that UNG2 encapsidation from
producer cells, while dispensable for replication of WT
viruses, was involved in the rescue of Vif-minus HIV-1 in
the presence of APOBEC3G [114]. Although all groups
target UNG2 inhibition or depletion (by the use of Ugi as
an inhibitor of UNG2 activity, UNG2 specific siRNA or
UNG2-/- mutants cells), it is difficult to reconcile these
conflicting data given that methodologies differ. How-
ever, two drawbacks have not been addressed. First, the
quasi-irreversibility of the binding of Ugi to UNG has
been demonstrated for pure E. Coli UDG [123,124] and
not for human UNG2 either pure or already engaged in its
interaction with HIV-1 integrase (IN). Therefore it
remains possible that the incoming Ugi associated to the
virally-encapsidated UNG2 may well dissociate by com-
petition with the vast excess of free UNG2 in the recipient
cells, leading to a functional UNG2-positive entering rep-
lication complex. Second, the EBV transformed B cell lines
from UNG-/- patients may well express high levels of EBV-
encoded dUTPase and/or UNG. Thus, the possibility
exists that EBV-encoded UNG could be packaged into
HIV-1 particles and compensates for the lack of human
UNG2 in the UNG-/- cell line. This hypothesis might be
verified by analyzing the EBV-transformed cell line for the
expression of EBV-encoded UNG and its packaging to
HIV-1. In addition, the expression of EBV-encoded dUT-
Pase will be sufficient to abrogate the cytoplasmic dUTP
pool levels. Therefore, the best approach to definitely con-
clude on the role of UNG2 in HIV-1 infectivity would be
the use of primary T lymphocyte or macrophages, instead
of EBV-transformed B cell lines, derived from UNG-/-
patients and would thus avoid some manipulations of
cells including overexpression of Ugi or RNA interference.
In addition, one can try to make his mind about the role
of UNG2 in the HIV-1 life cycle by some considerations of
evolutionary perspectives. Yang's data point to a positive
role of UNG2 packaging only when Vif is deficient, but are
neutral for a WT virus. It is difficult to pinpoint any evolu-
tionary forces, which could select for UNG2 packaging in
such a case. The Kaiser and Emerman data are consistent
with an accidental packaging of UNG2, an epiphenome-
non not related with any evolutionary advantage. Such
hypothesis would explain the lack of UNG2 packaging
into HIV-2 and SIV virions, two closely related cousins of
HIV-1, although no one has still looked at whether other
cellular UNGs might be encapsidated. In contradiction
with that hypothesis is the presence in all other non-pri-
mate lentiviruses of an enzymatic activity, so-called dUT-
Pase, in charge of preventing uracilation of their genome.
Given that all lentiviruses infect non-dividing macro-
phagic and dendritic cells as their main and common tar-
get cells, it is tempting to speculate that they acquired
means to use enzymatic activities enhancing their replica-
tion in the adverse context of nondividing cells. This
hypothesis is conforted by the fact that an ancestral dUT-
Pase gene was identified in the HIV-1 envelop gene [125].
Taken together, these data sustained the notion that the
presence of uracils in viral reverse transcripts is a constant
threat for HIV-1 replication. The virus consequently
evolved in developing strategies including both the
expression of the virally-encoded Vif protein to inhibit the
packaging of host-derived cytosine deaminase APOBEC
proteins and the packaging of host-encoded uracil DNARetrovirology 2008, 5:45 http://www.retrovirology.com/content/5/1/45
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glycosylase UNG2 to initiate uracil repair of misincorpo-
rated dUTP.
Concluding remarks
To date, considerable progress has been made in under-
standing the interactions between superior organisms and
their pathogens. The discovery of the APOBEC family
members has highlighted a central role for uracils as a bar-
rier against infectious agents, firstly as an actor of anti-
body diversification in adaptative immunity, and
secondly as a potent antiviral per se. This latter feature has
been particularly well documented in the case of infection
by HIV-1 and revealed how this virus faces up to the
uracilation of its genome. During the natural course of
HIV-1 infection, the Vif expression level in infected cells
seems to be sufficient to avoid extensive APOBEC3G-
mediated cytosine deamination of the viral genome that
otherwise will lead to error catastrophe. It remains possi-
ble however that some APOBEC3G proteins escape the
Vif-mediated degradation. This in turn could help in the
emergence of G-to-A mutations enhancing drug resistance
and immune escape processes of HIV-1. Likewise, UNG2
encapsidation level within viral particles seems to be suf-
ficient to prevent the dUTP incorporation in viral reverse
transcripts. However, nothing is known about the effi-
ciency of HIV-1 replication when infected cells exhibit
high levels of intracellular dUTP. Therefore, it may be
interesting to test whether enhancing artificially the dUTP
pool levels in HIV-1 infected cells may represent an alter-
native approach to antiviral therapy. This could be done
by inhibition of thymidylate synthase or dUTPase. The
development of drugs against these enzymatic activities
may deserve to be evaluated as a viable therapeutic
approach.
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